UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $54.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 279.21% from the stock’s current price.

Separately, Oppenheimer lowered their target price on shares of UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating for the company in a report on Friday, March 15th.

UroGen Pharma Stock Performance

UroGen Pharma stock opened at $14.24 on Thursday. The stock’s 50 day simple moving average is $16.38 and its two-hundred day simple moving average is $14.59. The stock has a market cap of $333.93 million, a price-to-earnings ratio of -3.82 and a beta of 1.07. UroGen Pharma has a fifty-two week low of $8.69 and a fifty-two week high of $24.13.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.05). The business had revenue of $23.53 million during the quarter, compared to analyst estimates of $22.30 million. On average, analysts predict that UroGen Pharma will post -3.59 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Jason Drew Smith sold 4,993 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total value of $78,589.82. Following the completion of the transaction, the general counsel now directly owns 18,824 shares in the company, valued at approximately $296,289.76. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, General Counsel Jason Drew Smith sold 4,993 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total value of $78,589.82. Following the completion of the transaction, the general counsel now directly owns 18,824 shares in the company, valued at approximately $296,289.76. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Schoenberg sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $14.05, for a total transaction of $168,600.00. Following the completion of the transaction, the insider now owns 139,437 shares of the company’s stock, valued at $1,959,089.85. The disclosure for this sale can be found here. Insiders sold a total of 20,782 shares of company stock worth $306,829 in the last three months. Insiders own 11.13% of the company’s stock.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds have recently modified their holdings of URGN. RA Capital Management L.P. bought a new stake in shares of UroGen Pharma during the 3rd quarter valued at $20,787,000. RTW Investments LP boosted its holdings in UroGen Pharma by 101.4% in the 4th quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock worth $25,902,000 after buying an additional 869,344 shares during the period. BlackRock Inc. boosted its holdings in UroGen Pharma by 285.9% in the 2nd quarter. BlackRock Inc. now owns 1,097,916 shares of the company’s stock worth $11,363,000 after buying an additional 813,377 shares during the period. Silverarc Capital Management LLC bought a new position in UroGen Pharma in the 3rd quarter worth $7,129,000. Finally, Millennium Management LLC boosted its holdings in UroGen Pharma by 292.8% in the 2nd quarter. Millennium Management LLC now owns 616,245 shares of the company’s stock worth $5,047,000 after buying an additional 459,341 shares during the period. Institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.